ATE495195T1 - Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e - Google Patents

Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e

Info

Publication number
ATE495195T1
ATE495195T1 AT07795599T AT07795599T ATE495195T1 AT E495195 T1 ATE495195 T1 AT E495195T1 AT 07795599 T AT07795599 T AT 07795599T AT 07795599 T AT07795599 T AT 07795599T AT E495195 T1 ATE495195 T1 AT E495195T1
Authority
AT
Austria
Prior art keywords
hgf
growth factor
hepatocyte growth
binding protei
protei
Prior art date
Application number
AT07795599T
Other languages
English (en)
Inventor
William Winston
S Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE495195T1 publication Critical patent/ATE495195T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT07795599T 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e ATE495195T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
ATE495195T1 true ATE495195T1 (de) 2011-01-15

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07795599T ATE495195T1 (de) 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e

Country Status (21)

Country Link
US (5) US7649083B2 (de)
EP (2) EP2361934A3 (de)
JP (3) JP4686634B2 (de)
KR (1) KR101196060B1 (de)
AR (1) AR061171A1 (de)
AT (1) ATE495195T1 (de)
AU (1) AU2007254942B2 (de)
BR (1) BRPI0712222B1 (de)
CA (1) CA2654025C (de)
CY (1) CY1111714T1 (de)
DE (1) DE602007011923D1 (de)
DK (1) DK2027156T3 (de)
HK (1) HK1129395A1 (de)
IL (2) IL195037A (de)
MX (1) MX2008014829A (de)
NO (1) NO345476B1 (de)
NZ (1) NZ573818A (de)
PL (1) PL2027156T3 (de)
PT (1) PT2027156E (de)
SG (1) SG158112A1 (de)
WO (1) WO2007143090A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI395756B (zh) 2003-07-18 2013-05-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
CA2654019A1 (en) * 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
ATE495195T1 (de) * 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
PL3009148T3 (pl) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
NZ586357A (en) 2007-11-30 2012-10-26 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
NZ588029A (en) * 2008-03-14 2012-12-21 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
WO2009148928A1 (en) 2008-05-29 2009-12-10 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
BRPI0917315B8 (pt) 2008-11-07 2021-05-25 Galaxy Biotech Llc anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
KR20130103734A (ko) 2010-08-31 2013-09-24 제넨테크, 인크. 바이오마커 및 치료 방법
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
BR112015000776A2 (pt) 2012-07-13 2017-08-15 Oncomed Pharm Inc Agentes de ligação à rspo3 e usos dos mesmos
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2985292A4 (de) * 2013-04-07 2016-12-21 Genrix(Shanghai) Biopharmacertical Co Ltd Antikörper des rezeptors des epidermalen wachstumsfaktors
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
MX2017001983A (es) * 2014-08-15 2017-05-23 Oncomed Pharm Inc Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
EP3193935A4 (de) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Behandlung von fibrotischen erkrankungen
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
EP4110917A1 (de) 2020-02-28 2023-01-04 InteRNA Technologies B.V. Mirna-193a zur förderung des immunogenen zelltods
CN116234814A (zh) * 2020-08-28 2023-06-06 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TWI395756B (zh) * 2003-07-18 2013-05-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
RU2007146986A (ru) 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2654019A1 (en) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
US9096664B2 (en) 2015-08-04
US8273355B2 (en) 2012-09-25
SG158112A1 (en) 2010-01-29
NO345476B1 (no) 2021-02-22
IL195037A (en) 2015-08-31
US20080108565A1 (en) 2008-05-08
EP2361934A2 (de) 2011-08-31
US7649083B2 (en) 2010-01-19
US20100173362A1 (en) 2010-07-08
IL219654A0 (en) 2012-06-28
KR101196060B1 (ko) 2012-11-01
US20140178935A1 (en) 2014-06-26
BRPI0712222A2 (pt) 2012-01-10
PT2027156E (pt) 2011-04-18
PL2027156T3 (pl) 2011-06-30
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
EP2027156B1 (de) 2011-01-12
US8580930B2 (en) 2013-11-12
JP2013090632A (ja) 2013-05-16
NO20085421L (no) 2009-02-27
MX2008014829A (es) 2009-01-29
EP2361934A3 (de) 2011-11-02
JP5735476B2 (ja) 2015-06-17
DE602007011923D1 (de) 2011-02-24
BRPI0712222B1 (pt) 2021-10-13
AU2007254942A1 (en) 2007-12-13
EP2027156B9 (de) 2011-03-30
CY1111714T1 (el) 2015-10-07
AU2007254942A8 (en) 2009-02-05
NZ573818A (en) 2011-09-30
JP4686634B2 (ja) 2011-05-25
US20110229462A1 (en) 2011-09-22
AU2007254942B2 (en) 2011-10-27
EP2027156A2 (de) 2009-02-25
WO2007143090A3 (en) 2008-03-13
KR20090027226A (ko) 2009-03-16
CA2654025C (en) 2016-08-02
CA2654025A1 (en) 2007-12-13
US20130203963A1 (en) 2013-08-08
IL195037A0 (en) 2011-08-01
JP2011072318A (ja) 2011-04-14
DK2027156T3 (da) 2011-04-26
JP2009539347A (ja) 2009-11-19
WO2007143090A2 (en) 2007-12-13
US7943344B2 (en) 2011-05-17
HK1129395A1 (en) 2009-11-27

Similar Documents

Publication Publication Date Title
ATE495195T1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
HK1129394A1 (en) Hepatocyte growth factor (hgf) binding proteins
NO20201120A1 (no) Bindingsvirkninger
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
DK2046826T3 (da) Exendin-fusionsproteiner
DK3118221T3 (da) Proteiner
NO20082030L (no) Styrt voltametri
DK2203551T3 (da) Bifidobakterieart
BRPI0815075A2 (pt) Aglutinantes
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
DK2040814T3 (da) Keramisk filter
DK2032551T3 (da) Antitumorale dihydropyran-2-on-forbindelser
FI20065201A0 (fi) Poikkisuuntainen venytyslaite
FI20075144L (fi) Intubaatioapuväline
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
FI20065625A0 (fi) Ilmanvaihdon päätelaite
DE112007000480A5 (de) Filtervorrichtung
FI20050547A0 (fi) Side
ITCN20060002A1 (it) Imbiellaggio martino
FIU20060058U0 (fi) Magneettisuodatin
UA13448S (uk) Радіотелефон
ES1064069Y (es) Invernadero
ES1067016Y (es) Puzzle magnetico
ES1063205Y (es) Sabana encimera
UA14472S (uk) Акваріумний комплекс

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2027156

Country of ref document: EP